GlassScriptPhysician profile
Meredith Hartman
NPI 1710366984
$6,811.81
in general payments reported to CMS, 2019-2025
26 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $493 · 2021: $918 · 2022: $993 · 2023: $1,081 · 2024: $1,672 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,772 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,772.44 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,515.04 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Glaukos Corporation | $735.31 | 2020-2025 | Idosetr, Istent Infinite, Idose |
| New World Medical,INC. | $673.06 | 2020-2024 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Biotissue Holdings INC. | $477.47 | 2024 | |
| Mallinckrodt Hospital Products INC. | $417.91 | 2021-2024 | Acthar |
| Rxsight INC | $325.15 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Allergan, INC. | $323.97 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $298.98 | 2024-2025 | Xdemvy |
| Abbvie INC. | $214.75 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $210.70 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $186.36 | 2020-2021 | |
| Carl Zeiss Meditec USA, INC. | $178.33 | 2022 | |
| Sight Sciences, INC. | $173.81 | 2021 | |
| The Cameron-Ehlen Group, INC. | $153.42 | 2020-2021 | |
| Harrow Eye, LLC | $152.36 | 2024-2025 | Vevye |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $147.46 | 2024-2025 | Purified Cortrophin Gel |
| Sun Pharmaceutical Industries INC. | $138.50 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $118.16 | 2025 | Catalys System, Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $108.03 | 2023 | |
| Rayner Intraocular Lenses Limited | $62.82 | 2023 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Dompe US, INC. | $55.90 | 2024-2025 | Oxervate |
| Ocular Therapeutix, INC. | $49.50 | 2021-2023 | Dextenza |
| Oyster Point Pharma, INC. | $33.82 | 2022 | |
| Mallinckrodt Enterprises LLC | $23.54 | 2019 | |
| Aerie Pharmaceuticals, INC. | $20.82 | 2020 | |
| Thea Pharma INC. | $16.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Hartman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.